Analysts Upgrade Tesla, CVS on Growth Potential; Downgrade DoorDash Over Student Loan Risks
-
Tesla upgraded to Overweight by Morgan Stanley on AI potential, services growth, $400 price target
-
CVS upgraded to Outperform by Wolfe on realistic guidance, Medicare Advantage upside, $80 price target
-
ImmunoGen upgraded to Overweight by JPMorgan on underappreciation of pipeline beyond lead drug
-
Etsy upgraded to Outperform by Wolfe citing attractive valuation after 46% YTD drop
-
DoorDash downgraded to Market Perform by MoffettNathanson on risk from ending student loan payment suspension